Products
Home > Therapeutic Peptides > APIs > Ziprasidone Hydrochloride Monohydrate

If you find Creative Peptides is useful to satisfy your needs, please do not hesitate to contact us!

Ziprasidone Hydrochloride Monohydrate

CAT#
10-101-129
Synonyms/Alias
CP-88059; 5-(2-(4-(1,2-Benzisothiazol-3-yl)piperazinyl)ethyl)-6-chlorooxindole · HCl · H2O
CAS No.
146939-27-7 (net), 138982-67-9 (hydrochloride monohydrate)
M.W/Mr.
467.42
Molecular Formula
C21H21ClN4OS·ClH·H2O
Source
Synthetic
Application
Ziprasidone hydrochloride monohydrate is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, acute mania and mixed states associated with bipolar disorder. Ziprasidone is also used off-label for depression, bipolar maintenance and PTSD.
Description
Ziprasidone (marketed as Geodon, Zeldox and Zipwell) was the fifth atypical antipsychotic to gain approval (February 2001) in the United States.
Areas of Interest
Bipolar disorder Schizophrenia

Useful Tools

Ziprasidone hydrochloride monohydrate is an atypical antipsychotic that displays combined SR-2A and D2DR inhibition. Ziprasidone displays high affinity at SR-2A receptors with a SR-2A/D2DR affinity ratio greater than any other clinically available atypical antipsychotics.

In the current work the kinetics of dehydration of ziprasidone hydrochloride monohydrate was studied by nonisothermal thermogravimetry. Ziprasidone hydrochloride monohydrate was heated from 30 to 150° with a heating rate of 5° per min under nitrogen gas atmosphere and weight loss data were collected. Powder X-ray difraction was used to characterize the solid before and after dehydration. The well accepted Coats-Redfern model fitting approach was applied to the thermogravimetry data for the kinetic analysis. Thirteen solid state reaction models were studied; among them one-dimensional diffusion model was found to be the best fit model for this reaction with an excellent correlation 0.9994. The Arrhenius parameters, activation energy, and pre-exponential factor were determined, the values were found to be 28 k.cal/mol and 9.53×1013 sec-1, respectively.

Ravikiran, A., Arthanareeswari, M., Kamaraj, P., & Praveen, C. (2013). Nonisothermal kinetics analysis of the dehydration of ziprasidone hydrochloride monohydrate by thermogravimetry. Indian journal of pharmaceutical sciences, 75(3), 361.

The findings of this study indicate that mild-to-moderate impairment of renal function does not result in clinically significant alteration of ziprasidone pharmacokinetics and therefore does not necessitate dose adjustment.

Aweeka, F., Jayesekara, D., Horton, M., Swan, S., Lambrecht, L., Wilner, K. D., ... & Turncliff, R. Z. (2000). The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. British journal of clinical pharmacology, 49(S1), 27-33.

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
Customer Support & Price Inquiry
  • Please enter the code "peptides"

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

Follow us on:

Copyright © 2008 - Creative Peptides. All rights reserved.

USA

Address: 45-16 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882

Fax: 1-631-614-7828

E-Mail:

Europe

Tel: 44-207-097-1828

E-Mail: